Clinical Trial Update: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pembrolizumab plus enzalutamide and ADT versus placebo plus enzalutamide and ADT in metastatic hormone-sensitive prostate cancer; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer

Drugs mentioned

• Androgen deprivation therapy (Androgen deprivation therapy)
• Enzalutamide (enzalutamide)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Metastatic Hormone-Sensitive Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2023-11-18